Business Context and Reporting Period
This Form 6-K filing by Midatech Pharma PLC (noted as Biodexa Pharmaceuticals Plc in metadata) covers the month of May 2020. The registrant is a foreign private issuer based in Cardiff, United Kingdom. The filing primarily announces a Registered Direct Offering in the United States and a concurrent UK Placing to raise capital, alongside the release of unaudited headline results for the fiscal year ended December 31, 2019.
Key Financial Metrics and Capital Raise
The filing details two distinct capital raising transactions expected to close in late May 2020:
- US Registered Direct Offering: Sale of 1,818,182 American Depositary Shares (ADSs) at $1.65 per ADS. Each ADS represents five ordinary shares.
- US Private Placement Warrants: Issuance of warrants exercisable for 1,818,182 ADSs (100% of the offering) at an exercise price of $2.05 per ADS, expiring 5.5 years from issuance.
- UK Placing: Sale of 6,666,666 Units (one share and one warrant per unit) at £0.27 per Unit. The UK Warrants have an exercise price of £0.34 per share and expire 5.5 years from issuance.
- Placement Agent Fees:
- US Agent (H.C. Wainwright): 7.0% cash fee, 1.0% management fee, plus expense allowances and warrants for 5.0% of the offering.
- UK Agent (Turner Pope): 7.0% cash fee, £15,000 corporate finance fee, plus warrants for 5.0% of the UK placing.
Historical Financials: The filing references unaudited headline results for the year ended December 31, 2019, but does not provide specific revenue, profit, cash flow, or debt figures within this text. Investors must refer to the incorporated press release (Exhibit 99.3) for these specific metrics.
Material Changes and Unusual Items
The primary material change is the significant dilution of existing shareholders resulting from the issuance of new ADSs and ordinary shares, as well as the issuance of warrants with immediate exercisability. The filing notes that the Warrant Securities are not registered under the Securities Act of 1933 and are offered pursuant to exemptions for accredited investors and qualified institutional buyers.
Guidance, Outlook, and Risks
Outlook: The transactions are expected to close on or about May 20, 2020 (US) and May 22, 2020 (UK), subject to customary closing conditions. The company intends to file a registration statement for the Warrant Shares within 120 days of issuance.
Risks and Contingencies:
- Closing Risk: The transactions are subject to conditions that may not be satisfied in a timely manner or at all.
- Market Conditions: Proceeds and results may be impacted by prevailing market conditions.
- Financial Accuracy: Actual 2019 results may differ from the unaudited headline figures once consolidated financial statements are finalized.
- Forward-Looking Statements: The company cautions against undue reliance on forward-looking statements regarding the closing and proceeds of the offerings.
Investor Verification Checklist
- Verify the final closing date and total gross proceeds of both the US Offering and UK Placing.
- Review the full text of the unaudited headline results for the year ended December 31, 2019 (Exhibit 99.3) to obtain specific revenue and loss figures.
- Confirm the effective date of the registration statement for the Warrant Shares to ensure resale eligibility.
- Assess the dilution impact of the 100% warrant coverage in the US offering and the 1:1 warrant ratio in the UK placing.
- Check for any subsequent filings regarding the finalization of the 2019 audited financial statements.